New from Oriola RWE Team: The clinical and economic burden of pneumonia and pneumococcal disease in Finland
Oriola's latest project investigates the burden of pneumonia and pneumococcal diseases in children and adults in Finland. Pneumococcal diseases are associated with over 800,000 deaths and an estimated 40 million years of life lost globally, being the leading cause of infection-related deaths in children under 5 years old [1]. Among infectious diseases, the most common cause of death is community-acquired pneumonia (CAP), which is defined as all-cause pneumonia, acquired in a community setting.
The project aims to explore the clinical and economic burden of invasive pneumococcal disease and community-acquired pneumonia in the Finnish population of all ages in terms of healthcare resource utilisation and work absenteeism. This nationwide population-based study compiles individual-level data from multiple unique healthcare databases and vital registers enabling us to form a comprehensive picture of direct and indirect disease burden and use of healthcare resources.
The Nordic countries offer ideal conditions for registry studies, with harmonised laws, electronic data collection, and nationwide cohort creation.
1 GBD 2019, Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2022;400(10369): 2221-2248.doi: 10.1016/S0140-6736(22)02185-7.
Why Oriola?
Oriola RWE team of experienced specialists offers a wide range of services, including feasibility studies, patient surveys, drug utilisation studies, and phase IV studies. Oriola RWE team provides strategic support across the entire lifespan of medical products including market research, landscape analyses, and data for health economic models to support market entry and pricing board decisions. Our unique digital platform for patient-reported outcomes (PRO) ensures GDPR-compliant data usage and transparent medical research with PRO data collected through Oriola’s Research Pharmacy Network (around 160 active pharmacies in Finland), patient organisations and private healthcare providers.
Get in touch with Oriola RWE Team:
Oriola - a Fingenious® Ecosystem Service Partner
The Fingenious® Ecosystem is a collaboration network in the field of health and biomedical research in Finland. Fingenious® Ecosystem supports you in your RWD/RWE by providing a single window into the Finnish service and data offering. Fingenious® Ecosystem Partners can help you tailor high-quality data permit applications, offer insight into longitudinal Finnish data sets, recognize the benefits that the Finnish legislation can offer, and much more. Explore the Fingenious® Ecosystem and discover new opportunities for your RWE research.
Contact us
How can we help you with your RWE research? Reach out to us using the contact form below, we are We are ready to assist you with your RWE research. Fill out the contact form below and we will reach out to you as soon as possible.